In an observational study, researchers report that the combination of casirivimab and imdevimab -- two monoclonal antibody treatments under Food and Drug Administration emergency use authorization -- keep high-risk patients out of the hospital when infected with mild to moderate COVID-19.
from Latest Science News -- ScienceDaily https://www.sciencedaily.com/releases/2021/08/210830081817.htm
from Latest Science News -- ScienceDaily https://www.sciencedaily.com/releases/2021/08/210830081817.htm
Monoclonal antibody treatment combo reduces hospitalization among high-risk patients with COVID-19
![Monoclonal antibody treatment combo reduces hospitalization among high-risk patients with COVID-19]()
Reviewed by cmakigo
on
August 30, 2021
Rating:
No comments:
Post a Comment